Kilitch Drugs (India) Limited (KILITCH.BO)
INR 341.85
(-2.37%)
INR 341.85
(-2.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 287.42 Million INR | 22.83% |
| 2022 | 206.49 Million INR | 58.89% |
| 2021 | 134.13 Million INR | 76.93% |
| 2020 | 79.84 Million INR | 179.5% |
| 2019 | 45.46 Million INR | -80.04% |
| 2018 | 112.85 Million INR | 25.77% |
| 2017 | 85.71 Million INR | 52020.31% |
| 2016 | 4.39 Million INR | 99.2% |
| 2015 | -28.04 Million INR | -136.34% |
| 2014 | -7.86 Million INR | 17.64% |
| 2013 | 25.02 Million INR | -125.1% |
| 2012 | 45.88 Million INR | -62.97% |
| 2011 | 1.04 Billion INR | -40.82% |
| 2010 | 222.8 Million INR | -7.76% |
| 2009 | 243.64 Million INR | 28.21% |
| 2008 | 188.4 Million INR | -0.85% |
| 2007 | 190.01 Million INR | 371.79% |
| 2006 | 40.27 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 16.58 Million INR | -43.93% |
| 2023 Q4 | 70.77 Million INR | 210.41% |
| 2023 Q1 | 67.4 Million INR | 5.07% |
| 2023 Q2 | 91.08 Million INR | 35.13% |
| 2023 Q3 | 22.79 Million INR | -74.97% |
| 2023 FY | - INR | 22.83% |
| 2022 Q2 | 41.92 Million INR | -4.53% |
| 2022 Q4 | 64.15 Million INR | 37.47% |
| 2022 FY | - INR | 58.89% |
| 2022 Q1 | 43.91 Million INR | -19.06% |
| 2022 Q3 | 46.66 Million INR | 11.32% |
| 2021 Q3 | 20.7 Million INR | -45.88% |
| 2021 Q1 | 19.57 Million INR | 6.67% |
| 2021 FY | - INR | 76.93% |
| 2021 Q4 | 54.25 Million INR | 162.05% |
| 2021 Q2 | 38.25 Million INR | 95.42% |
| 2020 FY | - INR | 179.5% |
| 2020 Q4 | 18.35 Million INR | -45.84% |
| 2020 Q3 | 33.88 Million INR | 0.25% |
| 2020 Q2 | 33.79 Million INR | 555.04% |
| 2020 Q1 | -7.42 Million INR | 10.82% |
| 2019 FY | - INR | -80.04% |
| 2019 Q1 | 6.46 Million INR | -83.11% |
| 2019 Q2 | 22.97 Million INR | 255.42% |
| 2019 Q3 | 22.1 Million INR | -3.79% |
| 2019 Q4 | -8.32 Million INR | -137.67% |
| 2018 FY | - INR | 25.77% |
| 2018 Q4 | 38.28 Million INR | 218.68% |
| 2018 Q3 | -32.26 Million INR | -150.81% |
| 2018 Q2 | 63.49 Million INR | 13.68% |
| 2018 Q1 | 55.85 Million INR | 0.0% |
| 2017 FY | - INR | 52020.31% |
| 2016 FY | - INR | 99.2% |
| 2015 FY | - INR | -136.34% |
| 2014 FY | - INR | 17.64% |
| 2013 FY | - INR | -125.1% |
| 2012 Q4 | 6.5 Million INR | -32.4% |
| 2012 Q3 | 9.62 Million INR | 449.86% |
| 2012 Q2 | 1.75 Million INR | -94.6% |
| 2012 FY | - INR | -62.97% |
| 2012 Q1 | 32.45 Million INR | 0.0% |
| 2011 FY | - INR | -40.82% |
| 2010 FY | - INR | -7.76% |
| 2009 FY | - INR | 28.21% |
| 2008 FY | - INR | -0.85% |
| 2007 FY | - INR | 371.79% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 97.011% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.535% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 95.812% |
| Granules India Limited | 8.6 Billion INR | 96.659% |
| Indoco Remedies Limited | 2.64 Billion INR | 89.142% |
| Achyut Healthcare Limited | 524 Thousand INR | -54752.099% |
| Ajanta Pharma Limited | 12.56 Billion INR | 97.713% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.812% |
| Alpa Laboratories Limited | 86.12 Million INR | -233.722% |
| Brooks Laboratories Limited | 41.72 Million INR | -588.806% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 87.804% |
| Bajaj HealthCare Limited | 444.51 Million INR | 35.34% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 80.567% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.674% |
| Eris Lifesciences Limited | 6.98 Billion INR | 95.886% |
| FDC Limited | 4.4 Billion INR | 93.47% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 97.466% |
| Gufic Biosciences Limited | 1.48 Billion INR | 80.586% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 95.811% |
| Ipca Laboratories Limited | 13.29 Billion INR | 97.839% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 11.14% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 447.438% |
| Lasa Supergenerics Limited | -65.08 Million INR | 541.649% |
| Laurus Labs Limited | 8 Billion INR | 96.41% |
| Lupin Limited | 36.96 Billion INR | 99.223% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.977% |
| Medicamen Biotech Limited | 245.66 Million INR | -17.001% |
| Medico Remedies Limited | 150.37 Million INR | -91.135% |
| Megasoft Limited | 284.73 Million INR | -0.946% |
| NATCO Pharma Limited | 18.79 Billion INR | 98.471% |
| Piramal Pharma Limited | 13.05 Billion INR | 97.798% |
| RPG Life Sciences Limited | 1.28 Billion INR | 77.571% |
| Sigachi Industries Limited | 883.39 Million INR | 67.464% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.792% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 93.855% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 33.2% |
| Unichem Laboratories Limited | 742.35 Million INR | 61.282% |
| Wanbury Limited | 985.49 Million INR | 70.834% |
| Windlas Biotech Limited | 781.72 Million INR | 63.232% |
| ZIM Laboratories Limited | 462.09 Million INR | 37.8% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.489% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 107.703% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.87% |
| Hester Biosciences Limited | 539.47 Million INR | 46.721% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 90.465% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 57.889% |
| Bal Pharma Limited | 345.59 Million INR | 16.831% |
| Strides Pharma Science Limited | 3.76 Billion INR | 92.365% |
| Venus Remedies Limited | 711.8 Million INR | 59.62% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 92.648% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 81.62% |
| Shilpa Medicare Limited | 2.58 Billion INR | 88.894% |
| Aarti Drugs Limited | 3.24 Billion INR | 91.152% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 88.973% |
| Suven Life Sciences Limited | -992.78 Million INR | 128.952% |
| Ind-Swift Limited | 1.06 Billion INR | 73.013% |
| Valiant Laboratories Limited | 12.73 Million INR | -2156.26% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 96.921% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 110.186% |
| Themis Medicare Limited | 562.6 Million INR | 48.912% |
| Hikal Limited | 2.69 Billion INR | 89.324% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.179% |
| Sequent Scientific Limited | 549.8 Million INR | 47.722% |
| Novartis India Limited | 1.26 Billion INR | 77.356% |
| Wockhardt Limited | 1.08 Billion INR | 73.387% |
| Jubilant Pharmova Limited | 8 Billion INR | 96.41% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -2100.467% |
| Neuland Laboratories Limited | 4.74 Billion INR | 93.947% |
| Morepen Laboratories Limited | 1.72 Billion INR | 83.347% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -64.294% |